Printer Friendly

TheraQuest Presents TQ-1015 Opioid Inflammatory Pain Results at the American Pain Society Meeting.

BLUE BELL, Pa., April 1 /PRNewswire/ -- TheraQuest Biosciences, a development stage pain management company, has unveiled new results from TQ- 1015, its potent abuse deterrent opioid agonist at the American Pain Society Annual Scientific Meeting in Boston. The study evaluated the effects of TQ- 1015 in inflammatory pain against mechanical allodynia and thermal hyperalgesia and compared its potency with morphine.

Michael Ossipov, PhD, Associate Professor in the Department of Pharmacology, University of Arizona College of Medicine and a noted expert in analgesic pharmacology, stated, "TQ-1015 produced dose-dependent reversal of tactile hyperesthesia and thermal hyperalgesia. The potency of TQ-1015 remained constant over the time-course of the study. Importantly, TQ-1015 retained its antinociceptive potency in the presence of inflammation. These results indicate that TQ-1015 is active against increased pain states associated with inflammation. It is consistently more potent than morphine, with a high degree of efficacy."

Najib Babul, PharmD, President and Chief Executive Officer of TheraQuest, stated, "TheraQuest is pleased to be presenting peer-review data from TQ-1015 at the American Pain Society, a premiere scientific venue which brings together basic scientists, clinical scientists and clinicians interested in the field of pain."

About TQ-1015

TQ-1015 is being developed for the treatment of chronic cancer and non- cancer pain. It is a once-a-day sustained release opioid analgesic in a proprietary, abuse deterrent drug delivery system. It cannot be crushed for inhalation or obtaining rapid euphoria. It is also exceedingly difficult for I.V. abusers to extract the active drug from the formulation using common solvents.

TQ-1015 is significantly more potent than current therapies and it has a lower side effect profile than other opioids. The target population includes patients with moderate to severe chronic cancer and non-cancer pain. TQ-1015 will compete in the same market segment as MS Contin(R), OxyContin(R), Duragesic(R) and Palladone(TM).

About TheraQuest Biosciences

TheraQuest Biosciences, LLC is a private, development-stage pain management company building a diversified portfolio of pharmaceutical products to address a critical area of unmet medical need. Despite their limitations, current treatments for acute and chronic pain yield worldwide sales in excess of $25 billion. The TheraQuest team has contributed to the development of numerous analgesics approved in the U.S. over the past 20 years. TheraQuest's strategy is to use its expertise to identify, develop and commercialize product candidates with strong market potential that have lower development costs and reduced regulatory risk than new chemical entities. TheraQuest is headquartered in Blue Bell, Pennsylvania.

TheraQuest is funded in part by BioAdvance, the Biotechnology Greenhouse of Southeastern Pennsylvania and Ben Franklin Technology Partners of Southeastern Pennsylvania. Additional information is available at

CONTACT: Najib Babul, PharmD, CEO, TheraQuest Biosciences, LLC, +1-610-272-2071,

Web site:
COPYRIGHT 2005 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2005 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Apr 1, 2005
Previous Article:Radware Announces Earnings Conference Call.
Next Article:VWR International Acquires Irish Laboratory Supply Distributor, AGB Scientific Ltd.

Terms of use | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters